VOR Vor Biopharma Inc

Price (delayed)

$14.38

Market cap

$779.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$70.13

Enterprise value

$612.09M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that ...

Highlights
The debt has plunged by 90% YoY and by 2% from the previous quarter
Vor Biopharma's quick ratio has soared by 69% from the previous quarter
VOR's EPS has plunged by 132% YoY
The net income has contracted by 27% from the previous quarter

Key stats

What are the main financial stats of VOR

VOR stock price

How has the Vor Biopharma stock price performed over time
Intraday
6.99%
1 week
-4.2%
1 month
-2.24%
1 year
214.66%
YTD
9.94%
QTD
-19.39%

Financial performance

How have Vor Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$373.51M
Net income
-$883.08M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 27% from the previous quarter

Price vs fundamentals

How does VOR's price correlate with its fundamentals

Growth

What is Vor Biopharma's growth rate over time

Valuation

What is Vor Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VOR's EPS has plunged by 132% YoY
Vor Biopharma's equity has increased by 8% from the previous quarter

Efficiency

How efficient is Vor Biopharma business performance
The return on assets has dropped by 181% year-on-year but it has grown by 10% since the previous quarter
The return on invested capital has surged by 73% since the previous quarter

Dividends

What is VOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VOR.

Financial health

How did Vor Biopharma financials performed over time
Vor Biopharma's total assets is 23% less than its total liabilities
Vor Biopharma's current ratio has soared by 71% from the previous quarter
Vor Biopharma's quick ratio has soared by 69% from the previous quarter
The debt is 102% more than the equity
Vor Biopharma's debt to equity has shrunk by 104% YoY
The debt has plunged by 90% YoY and by 2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.